Industry Collaboration Aims to Set New Standard in Clinical Chain-of-Identity and Pharmaceutical Supply Chain Security

p-Chip Corporation, Choice One Rx, and RxERP, today announced a partnership to conduct a precedent-setting trial demonstrating end-to-end digital traceability. The trial will demonstrate advanced traceability of drugs for Oncology, Urology, Rheumatology and Gastroenterology across pharmaceutical supply chains for over 1,000 patients through to 2028. The trial is designed to validate compliance with the U.S. Drug Supply Chain Security Act (DSCSA) to establish verifiable Chain-of-Identity and Chain-of-Custody for individual prescriptions. The trial is co-sponsored by Avantor, a leading global provider of mission-critical laboratory and clinical consumables for the life sciences and healthcare sectors.

The trial leverages p-Chip’s unique Light Activated Microtransponders (MTPs) that are permanently embedded into individual prescription vials and containers to enable unit-level serialization. Each MTP emits a highly secure encrypted digital ID that is unique, unclonable and unalterable that enables traceability across pharmacy operations through Choice One Rx, and supply chain orchestration through RxERP, with Avantor supporting the initiative as a co-sponsor to advance security in pharmaceutical supply chain integrity.

Traditional adhesive labeling approaches such as barcodes and RFIDs are vulnerable to damage, theft, and copying for misappropriation to non-compliant or counterfeit pharmaceuticals. Additionally, traditional labeling methods do not survive the extreme low temperatures for cryogenic storage and shipping for thermolabile medications in cold chain supply logistics.

Unlike traditional DSCSA implementations that rely primarily on serialized barcodes and disconnected data linkages, this trial will demonstrate and evaluate how permanently embedded, tamper-resistant digital MTPs can maintain a continuous and auditable connection between a drug’s physical form and its digital record—enabling a true Chain-of-Identity and Chain-of-Custody from origin to administration for individual patients under DSCSA compliance.

“DSCSA compliance depends on confidence in the identity of the product at every point in the supply chain,” said Michael Hadjisavas, COO Life Sciences & Healthcare at p-Chip Corporation. “This trial demonstrates how permanent and immutable, unit-level digital identity in pharmaceutical product packaging can support regulatory requirements while laying the groundwork for a more trusted and resilient pharmaceutical ecosystem.”

Validating DSCSA-Aligned Traceability in Real-World Environments

The trial is designed to demonstrate and evaluate MTPs for DSCSA-aligned use cases, including:

• Unit-level identification and authentication using p-Chip��s embedded MTPs
• Secure linkage between physical drug units to their digital transaction and verification records
• Interoperable data exchange across pharmacy operations and ERP systems
• Verification at dispense within a licensed pharmacy environment
• Audit-ready traceability to support DSCSA compliance requirements

Choice One Rx will serve as the live pharmacy environment, validating operational feasibility, while RxERP will provide the necessary System-of-Record infrastructure required for compliance, verification, and reporting.

“Pharmacies are where DSCSA compliance is critical for operational excellence and compliance,” said Mr. MJ Bixby, CEO at Choice One Rx. “This trial shows how Chain-of-Identity can be preserved through dispensing workflows without disrupting patient care.”

“Interoperability and identity continuity are essential to scalable DSCSA compliance,” said Steve Madsen, CEO at RxERP. “By integrating unit-level digital identity into enterprise pharmacy systems, this trial demonstrates a practical and extensible approach to verification and compliance.”

“As a co-sponsor, Avantor supports initiatives that advance supply chain transparency, product integrity, and patient safety,” said Michael Kazinski, Vice President Precision Plastics at Avantor. “This trial reflects the kind of cross-industry collaboration needed to modernize pharmaceutical traceability.”

Establishing a Foundation for Future Supply Chain Integrity for Pharmaceuticals

In addition to DSCSA compliance, the collaborators view the trial as a foundational effort to support broader supply chain capabilities, including enhanced counterfeit detection, diversion prevention, automated recalls, and improved product confidence.

By successfully demonstrating digital traceability and Chain-of-Identity enablement, this trial seeks to provide an actionable framework for DSCSA compliance and inspire industry-wide adoption of interoperable, secure supply chain technologies. The outcome is expected to help mitigate risks associated with counterfeit drugs and support regulatory efforts to protect patient health and safety.

About p-Chip Corporation

p-Chip Corporation provides tiny, durable, light-activated microtransponder tags and software that create secure digital identities for physical items, enabling traceability, authentication, and data-driven supply chains. Together, these technologies function as a digital anchor for physical products, delivering breakthrough visibility and indexability at a scalable price point. The p-Chip® microtransponder is a tiny silicon chip – about the size of a grain of salt – that can be embedded into or attached onto products to assign a secure, unchangeable digital identity. p-Chip's platform is transforming how industries like healthcare, life sciences, food and automotive ensure the integrity of their products. For more information, visit www.p-chip.com.

About Choice One Rx

Choice One Rx is a leading independent specialty pharmacy for chronic and complex conditions that serves the South-eastern US. The Company specializes in supply chain operations for pharmaceuticals and in-home infusions to simplify orders, fulfillment, scheduling and delivery. Its mission is to disrupt and remove operational inefficiencies related to insurance pre-approvals, reimbursements, packaging and order fulfillment to reduce costs, and improve patient outcomes. The Company leads for short processing and turnaround time for same-day orders, 2-day shipping, and seamless refill orders. The Company empowers providers and patients for better health, convenience and overall experience. For more information, visit www.Choice One Rx.com.

About RxERP

RxERP is a cloud-hosted, pharmaceutical-first ERP platform that embeds unit-level serialization directly into core ERP workflows—creating a single, coordinated system of record for compliance, operations, and trading-partner data. Designed by pharma experts for pharma teams, RxERP helps automate regulatory requirements, including DSCSA regulations, while improving visibility across complex pharmaceutical supply chains. By unifying serialized data with order, inventory, quality, and financial processes, RxERP delivers actionable analytics that support stronger execution, better decisions, and revenue growth. For more information, visit https://rxerp.com/.

About Avantor

Avantor is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113478193/en/

“This trial demonstrates how permanent and immutable, unit-level digital identity in pharmaceutical product packaging can support regulatory requirements while laying the groundwork for a more trusted and resilient pharmaceutical ecosystem.”